Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsProspect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsVaccine-based immunotherapeutic approaches to gliomas and beyond
/in Dendritic Cells, Glioblastoma, International PublicationsA phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
/in Dendritic Cells, Glioblastoma, International PublicationsSensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenDendritic cell based vaccination strategy: an evolving paradigm
/in Dendritic Cells, Glioblastoma, International PublicationsLong-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
/in Dendritic Cells, Glioblastoma, International PublicationsTargeting the PD-1 pathway in pediatric solid tumors and brain tumors
/in Brain Tumors in Children, Checkpoint-Inhibitors, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer